7
Î In patients with HAP/VAP caused by Acinetobacter species, ATS
and IDSA suggest treatment with either a carbapenem or ampicillin/
sulbactam if the isolate is susceptible to these agents (W-L).
Î In patients with HAP/VAP caused by Acinetobacter species that is
sensitive only to polymyxins, ATS and IDSA recommend intravenous
polymyxin (colistin or polymyxin B) (S-L), and ATS and IDSA suggest
adjunctive inhaled colistin (W-L).
Î In patients with HAP/VAP caused by Acinetobacter species that is
sensitive only to colistin, ATS and IDSA suggest NOT using adjunctive
rifampicin (W-M).
Î In patients with HAP/VAP caused by Acinetobacter species, ATS and
IDSA recommend against the use of tigecycline (S-L).
Î In patients with HAP/VAP caused by a carbapenem-resistant pathogen
that is sensitive only to polymyxins, ATS and IDSA recommend
intravenous polymyxins (colistin or polymyxin B) (S-M), and ATS and
IDSA suggest adjunctive inhaled colistin (W-L).
Î For patients with VAP, ATS and IDSA recommend a 7-day course of
antimicrobial therapy rather than a longer duration (S-M).
Î For patients with HAP, ATS and IDSA recommend a 7-day course of
antimicrobial therapy (S-VL).
Î For patients with HAP/VAP, ATS and IDSA suggest that antibiotic
therapy be de-escalated rather than fixed (W-VL).
Î For patients with HAP/VAP, ATS and IDSA suggest using PCT levels
plus clinical criteria to guide the discontinuation of antibiotic therapy,
rather than clinical criteria alone (W-L).
Î For patients with suspected HAP/VAP, ATS and IDSA suggest NOT
using the CPIS to guide the discontinuation of antibiotic therapy (W-L).
S, strong ; W, weak strength of recommendation
H, high; M, moderate; L, low; VL, very low quality of evidence
